Piramal Pharma Ltd

Piramal Pharma Ltd is down for a fifth straight session today. The stock is quoting at Rs 193, down 1.25% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.14% on the day, quoting at 25609.05. The Sensex is at 83614.62, up 0.09%.Piramal Pharma Ltd has lost around 2.32% in last one month.Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has increased around 0.57% in last one month and is currently quoting at 22379.85, down 0.22% on the day. The volume in the stock stood at 12.78 lakh shares today, compared to the daily average of 35.33 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 193.39, down 1.49% on the day. Piramal Pharma Ltd tumbled 22.98% in last one year as compared to a 7.23% rally in NIFTY and a 0.81% spurt in the Nifty Pharma index.The PE of the stock is 36.8 based on TTM earnings ending September 25.Powered by Capital Market - Live

Revenue from operations for the period under review declined 8.83% year-on-year (YoY) to Rs 2,043.72 crore. The YoY performance was impacted by inventory destocking by a customer in one large CDMO order. EBITDA fell 44% YoY to Rs 224 crore in Q2 FY26 from Rs 403 crore in Q2 FY25. The EBITDA margin contracted to 11% in Q2 FY26 from 18% in the corresponding quarter last year. The company reported a pre-tax loss of Rs 46.18 crore in the September 2025 quarter, compared with a profit before tax of Rs 120.12 crore in the same period last year. On a half-year basis, the company reported a consolidated net loss of Rs 180.92 crore in H1 FY26, compared with a net loss of Rs 66.05 crore recorded in the same period last year, while revenue declined 5.13% year-on-year (YoY) to Rs 3,977.44 crore in H1 FY26. Nandini Piramal, chairperson, Piramal Pharma, said 'YoY growth in the CDMO Business was primarily impacted by inventory destocking in one large on-patent commercial product. Inconsistent recovery in US biopharma funding along with uncertainties on global trade policies led to adverse impact on order inflows and customer decision making during H1FY26. However, in the months of September and October 2025, we have seen a significant pick up in biopharma funding, which if sustains, should lend impetus to increased RFPs and orders going forward. Also, we are seeing strong customer interest for onshore offerings which bodes well for the investments we have made in our overseas sites. In our CHG business we further strengthened our leadership position in the US Sevoflurane market, while simultaneously working to obtain regulatory approvals for ex-US markets from our India plant. Our consumer business delivered healthy mid-teen growth, seamlessly collaborating with various stakeholders for smooth transition to new GST rates changes.' Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. The scrip rose 0.45% to currently trade at Rs 201.40 on the BSE. Powered by Capital Market - Live

Net loss of Piramal Pharma reported to Rs 99.22 crore in the quarter ended September 2025 as against net profit of Rs 22.59 crore during the previous quarter ended September 2024. Sales declined 8.83% to Rs 2043.72 crore in the quarter ended September 2025 as against Rs 2241.75 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales2043.722241.75 -9 OPM %7.7615.24 - PBDT156.66312.34 -50 PBT-46.18120.12 PL NP-99.2222.59 PL Powered by Capital Market - Live

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 5 November 2025.Powered by Capital Market - Live

Piramal Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 202.92, up 2.86% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.81% on the day, quoting at 26078.15. The Sensex is at 85221.98, up 0.94%. Piramal Pharma Ltd has added around 3.35% in last one month. Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has added around 1.79% in last one month and is currently quoting at 22515.7, up 0.28% on the day. The volume in the stock stood at 38.48 lakh shares today, compared to the daily average of 32.46 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 203.94, up 3.36% on the day. Piramal Pharma Ltd is down 20.68% in last one year as compared to a 6.88% gain in NIFTY and a 0.03% gain in the Nifty Pharma index.The PE of the stock is 36.43 based on TTM earnings ending June 25.Powered by Capital Market - Live

Piramal Pharma Solutions and NewAmsterdam Pharma Company N.V. today announced the opening of a dedicated oral solid dosage (OSD) form suite at Piramal's facility in Sellersville, Pennsylvania, USA. As one of Piramal Pharma Solutions' focused drug product facilities, the Sellersville site provides comprehensive development and manufacturing services for various formulations, including several forms of OSDs. This addition will increase operational efficiency, helping NewAmsterdam Pharma to deliver its investigational drug therapy, if approved, to patients in need. The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities. This includes a reconfiguration of existing space to create a dedicated OSD suite that will be used exclusively for fixed dose combination products. The new suite is designed for turnkey, multi-layer tablet production, equipped with advanced capabilities and technology to support granulation, compression, tableting, and coating. This suite will facilitate the production of NewAmsterdam Pharma's investigational FDC, a non statin cholesterol medication to reduce LDL-C. Although the suite is essential to the FDC's production, the partnership between Piramal Pharma Solutions and NewAmsterdam Pharma extends beyond the Sellersville site. Piramal's Ahmedabad PPDS, India site played a crucial role in the product's development, while its Pithampur, India site provides dual sourcing support. Powered by Capital Market - Live

The Board of Piramal Pharma at its meeting held on 28 July 2025 has approved the grant of 20,20,507 stock options under ESOP. Powered by Capital Market - Live

Revenue from operations for the period under review declined by 1% year-over-year (YoY) to Rs 1,934 crore. EBITDA fell by 26% to Rs 165 crore in Q1 FY26 from Rs 224 crore in Q1 FY25. EBITDA margin for Q1 FY26 was 9% as against 11% in Q1 FY25, primarily impacted by inventory destocking. This was partly offset by improved profitability of the overseas facilities in the CDMO business. The company posted a pre-tax loss of Rs 79 crore in the June'25 quarter as against a pre-tax loss of Rs 45 crore registered in the same period last year. Nandini Piramal, chairperson, Piramal Pharma, said: 'Excluding the impact of destocking in one large on-patent commercial product, our CDMO business delivered mid-teen revenue growth during the quarter accompanied by improvement in EBITDA margin, especially at our overseas sites. Growth in our CHG business is also expected to pick up for the remaining part of the year given the timing of some of the institutional orders. Our consumer business delivered healthy growth, in-line with our expectations, driven by power brands and e commerce sales. Withstanding the near-term challenges, we believe we are on track to achieve our FY2030 aspirations of becoming a $2 billion revenue company with 25% EBITDA margin and high-teen ROCE.' Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. The scrip tumbled 4.80% to currently trade at Rs 194.55 on the BSE. Powered by Capital Market - Live

Net Loss of Piramal Pharma reported to Rs 81.70 crore in the quarter ended June 2025 as against net loss of Rs 88.64 crore during the previous quarter ended June 2024. Sales declined 0.89% to Rs 1933.71 crore in the quarter ended June 2025 as against Rs 1951.14 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales1933.711951.14 -1 OPM %5.5210.48 - PBDT97.52139.47 -30 PBT-99.76-45.08 -121 NP-81.70-88.64 8 Powered by Capital Market - Live

Piramal Pharma announced that the Administrative Committee of the Board, at its meeting held today, has approved execution of a sale deed and ancillary definitive agreements with Global Pharma (Buyer) for the sale of decommissioned unit located at A-159, MIDC, Wagle Industrial Estate, Thane West - 400604 for a proposed consideration of approximately Rs. 8.50 core plus applicable taxes. The transaction is expected to conclude within 90 days, subject to fulfilment of conditions as described in the sale deed. The company added, We reiterate that the unit is decommissioned and contributed Nil to the Company's turnover, income, and net worth in the last financial year. Accordingly, sale will have no impact on Company operations.Powered by Capital Market - Live